A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-11

Study Completion Date

2022-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

NCT05906836

Healthy

COMPLETED PHASE1

Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers

NCT01178853

Healthy

COMPLETED PHASE4

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

NCT03717064

Healthy Volunteers

COMPLETED PHASE1

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

NCT04515628

Healthy Participants

COMPLETED PHASE1

Drug Interaction Study With Rosuvastatin

NCT02101125

Immunosuppression For Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rosuvastatin + Pirtobrutinib

Participants received study intervention through oral administration as follows:

* Day 1: 20 milligram (mg) rosuvastatin alone
* Day 6: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib
* Days 7 to 12: Once daily (QD) doses of 200 mg pirtobrutinib alone
* Day 13: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib
* Days 14 to 17: QD doses of 200 mg pirtobrutinib alone.

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

Administered Orally.

Pirtobrutinib

Intervention Type DRUG

Administered Orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin

Administered Orally.

Intervention Type DRUG

Pirtobrutinib

Administered Orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3527727

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs.
* Body mass index (BMI) within the range of 18.0 to 32.0 kilograms per meter squared (kg/m²) and a body weight of at least 50 kg.
* Males, or female participants who are not of childbearing potential.

Exclusion Criteria

* Have known allergies to pirtobrutinib or rosuvastatin, related compounds, or any components of the formulation.
* Have an abnormal blood pressure and/or pulse rate, deemed to be clinically significant by the investigator.
* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorder or surgery (including cholecystectomy) capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data.
* Have used or intend to use prescription or nonprescription medication (including dietary supplements, vitamins, and/or herbal medications), or modulators of CYP3A4 or BCRP within 7 days prior to dosing, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.
* Have c.34AA, c.421AA, or c.34GA/421CA genotypes of ABCG2 as determined through genotyping.
* Have c.521TC and c/521CC genotypes of SLCO1B1 as determined by genotyping.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes